Background: Imatinib, given concurrently or alternating with chemotherapy, has improved the response and survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) but relapses are still frequent. The aim of this study was to evaluate the feasibility and results of giving imatinib concurrently with intensive chemotherapy, stem cell transplantation and post-transplant imatinib maintenance therapy in patients with newly diagnosed Ph+ ALL. Design and Methods: This was a phase II study of patients with newly diagnosed Ph + ALL given standard chemotherapy, together with imatinib (400 mg/day) until stem cell transplantation, followed by imatinib maintenance therapy for all patients regardless of the molecular status of the disease. Results: Of the 30 patients included, 27 (90%) achieved complete remission, one was resistant to treatment and two died during induction therapy. The percentages of major and complete molecular responses were 86% and 21% after induction, and 81% and 65% after consolidation, respectively. Similar results were observed assessing minimal residual disease by flow cytometry. Of the 27 patients who achieved complete remission, 21 underwent stem cell transplantation (16 allogeneic, 5 autologous). Imatinib (400 mg/day) could be administered after transplantation for a median of 3.9 months in 12 patients, although it was interrupted in 10 patients (in 2 cases because of side effects of the drug). Nine patients relapsed, four before and five after stem cell transplantation and eight patients died of transplant-related causes. With a median follow-up of 4.1 years, the probabilities (95% CI) of diseasefree and overall survival were 30% (15% to 45%) and 30% (16% to 45%), respectively. Conclusions: These results confirm that imatinib is an effective first-line treatment for adult Ph + ALL when given concurrently with chemotherapy, making stem cell transplantation feasible in a high proportion of patients. However, post-transplantation imatinib administration was limited, mainly because of transplantation-derived complications rather than drug-specific toxicity.
IGHV gene analysis in chronic lymphocytic leukemia / F. Maura, G. Gritti, G. Reda, K. Aprile Von Hohenstaufen Puoti, V. Ferla, M. Sciumè, L. Cro, M. Pomati, S. Fabris, M. Lionetti, L. Baldini, A. Neri, G. Lambertenghi Deliliers, A. Cortelezzi. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 95:suppl.3(2010), pp. 87-87. ((Intervento presentato al 11. convegno Congress of the Italian Society of Experimental Hematology tenutosi a Torino nel 2010.
|Titolo:||IGHV gene analysis in chronic lymphocytic leukemia|
GRITTI, GIUSEPPE (Secondo)
LAMBERTENGHI DELILIERS, GIORGIO (Penultimo)
CORTELEZZI, AGOSTINO (Ultimo)
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||2010|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3324/haematol.2009.011221|
|Appare nelle tipologie:||01 - Articolo su periodico|